Результаты поиска

Geriatric chronic recurrent multifocal osteomyelitis (CRMO) mimicking multifocal multiple myeloma: a first in an octogenarian.

Chronic recurrent multifocal osteomyelitis (CRMO), an autoinflammatory bone disorder characterized by non-bacterial osteomyelitis causing recurrent multifocal bone lesions, is a well-known, yet uncommon pediatric condition that rarely affects adults; to date, it has never been diagnosed over the age of 75. The following report will discuss the first octogenarian diagnosed with CRMO and therefore represents an exceptionally rare presentation of a rare disease. An 83-year-old woman presented with progressive right shoulder, forearm, and hip pain, with associated weight loss and global weakness,

Совпадение в полном тексте источника
… Jansson AF Muller TH Gliera L Ankerst DP Wintergerst U Belohradsky BH Clinical score for nonbacterial osteitis in children and adults Arthritis Rheum. 2009 60 4 1152 1159 10.1002/art.24402 19333943 Jansson AF, Muller TH, Gliera L, Ankerst DP, Wintergerst U, Belohradsky BH, et al. … Arthritis Rheum. 2009;60(4):1152–9. 19333943 10.1002/art.24402 10. …

New Insights and Future Perspectives of APRIL in IgA Nephropathy.

IgA nephropathy (IgAN) is characterized by immune-mediated glomerulonephritis, with the accumulation of galactose-deficient IgA1 (Gd-IgA1) in the glomeruli and increased levels of circulating Gd-IgA1 and Gd-IgA1-containing immune complexes. An incomplete understanding of the underlying mechanisms and differences in clinical and pathological features between individuals and ethnicities has contributed to the lack of established treatments for IgAN. A tumor necrosis factor (TNF) family member, a proliferation-inducing ligand (APRIL), is a crucial cytokine essential for the generation and surviva

Совпадение в полном тексте источника
… Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus Arthritis Rheum. 2009 60 2083 2093 10.1002/art.24628 19565488 48. Makita Y. Suzuki H. Kano T. Takahata A. Julian B.A. Novak J. Suzuki Y. … Rheum. Dis. 2018 77 883 889 10.1136/annrheumdis-2018-213032 29563108 76. Barratt J. Hislop C. Pennington J. FR-PO1128 effects of blisibimod, a selective inhibitor of B-cell activating factor, in patients with IgA nephropathy J. Am. Soc. Nephrol. 2016 27 4B 77. Kaegi C. Steiner U.C. Wuest B. …

Towards an adiposity-related disease framework for the diagnosis and management of obesities.

Obesity is a complex disease that relapses frequently and associates with multiple complications that comprise a worldwide health priority because of its rising prevalence and association with numerous complications, including metabolic disorders, mechanic pathologies, and cancer, among others. Noteworthy, excess adiposity is accompanied by chronic inflammation, oxidative stress, insulin resistance, and subsequent organ dysfunction. This dysfunctional adipose tissue is initially stored in the visceral depot, overflowing subsequently to produce lipotoxicity in ectopic depots like liver, heart,

Совпадение в полном тексте источника
… Ann Rheum Dis. 2014;73:1914–1922. doi: 10.1136/annrheumdis-2014-205459. 59. DeMarco MAMA, Maynard JW, Huizinga MM, et al. Obesity and younger age at gout onset in a community-based cohort. Arthritis Care Res. 2011;63:1108–1114. doi: 10.1002/acr.20479. 60. … Ann Rheum Dis. 2017;76:1870–1882. doi: 10.1136/annrheumdis-2017-211472. 61. Deng Y-T, Li Y-Z, Huang S-Y, et al. Association of life course adiposity with risk of incident dementia: a prospective cohort study of 322,336 participants. …

CAR T клеточная терапия в неврологических расстройствах, вызванных автоантибиозами: многообещающая стратегия.

Клеточная терапия химерного антигенного рецептора (CAR) Т становится перспективным подходом к неврологическим аутоиммунным расстройствам на базе клеток B, особенно тем, которые характеризуются патогенными автоантиорганизмами, направленными на ключевые нейронные структуры. Эти заболевания, включая расстройство спектрального спектра нейромиелита, миастения гравис, синдром Ламберта-Итона миастеника, болезнь, связанная с антителами MOG, энцефалит рецептора против NMDA, диацилглицирол губазы альфа антитела, ассоциируемый с энцефалитом, синдромом жесткого человека и множественным склерозом, могут бы

Obinutuzumab Treatment in Rituximab- and Bortezomib-Resistant Phospholipase A2 Receptor Antibody-Positive Membranous Nephropathy.

Primary membranous nephropathy (MN) is a frequent cause of nephrotic syndrome in adults and is commonly linked to circulating autoantibodies against the M-type phospholipase A2 receptor (PLA2R). Rituximab has proven effective as a B-cell-depleting therapy in many patients; however, a significant proportion eventually develop resistance. We report the case of a 54-year-old man with PLA2R antibody-positive primary MN who did not respond to multiple immunosuppressive therapies, including cyclophosphamide, calcineurin inhibitors, repeated rituximab courses, and bortezomib. Despite ongoing nephroti

Совпадение в полном тексте источника
… Ann Rheum Dis. 2022;81:100–107. doi: 10.1136/annrheumdis-2021-220920. 12. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Mössner E, Brünker P, Moser S, et al. …

Development Trends of Janus Kinase Inhibitors (JAKi) Over Three Decades: From Common to Rare Diseases.

Janus kinase inhibitors (JAKi) have undergone three decades of research and development, demonstrating substantial therapeutic efficacy and broad clinical applicability in autoimmune diseases, inflammatory disorders, hematopoietic malignancies, and a spectrum of rare diseases. However, their research and development are constrained by three key challenges: the difficulty in target selection and safety concerns arising from their effects on cellular signaling pathways, as well as the challenges in formulating optimal dosing regimens due to interindividual variability in pharmacokinetics. In thi

Совпадение в полном тексте источника
… Ann Rheum Dis . 2025 ; 84 ( 5 ): 664 – 679 . doi: 10.1016/j.ard.2025.01.032 40037995 58. Konzett V , Smolen JS , Nash P , et al. … Ann Rheum Dis . 2021 ; 80 ( 1 ): 71 – 87 . doi: 10.1136/annrheumdis-2020-218398 33158881 PMC7788060 68. Zhang C , Lai F , Gong H , et al. A novel dual Bruton’s tyrosine kinase/janus kinase 3 inhibitor Wj1113 and its therapeutic effects on rheumatoid arthritis . …

Nurse-led web-based self-management program to improve patient activation and health outcomes in patients with chronic low back pain: an acceptability and feasibility pilot study.

BackgroundPatients with chronic low back (cLBP) pain report reduced physical function and ability to participate in social roles and are more likely to use opioid pain medications. While self-management interventions have been shown to support these patients, their effectiveness has been limited due to poor patient engagement. "Patient activation" encompasses the skills, knowledge, and motivation that a person has to manage their health. Supporting patient activation may improve the effectiveness of self-management for cLBP.MethodsIn this single-masked pilot study of adults with cLBP, patients

Совпадение в полном тексте источника
… Arthritis Rheum. 2008;59:1009–17. 18576310 10.1002/art.23817 21. … Arthritis Rheum. 1993;36:439–46. 8457219 10.1002/art.1780360403 37. …

Tackling the cytokine storm in COVID-19, challenges and hopes.

The outbreak of Coronavirus disease 2019 (COVID-19) is the current world health concern, presenting a public health dilemma with ascending morbidity and mortality rates exceeding any previous viral spread, without a standard effective treatment yet. SARS-CoV-2 infection is distinguished with multiple epidemiological and pathological features, one of them being the elevated levels of cytokine release, which in turn trigger an aberrant uncontrolled response known as "cytokine storm". This phenomenon contributes to severe acute respiratory distress syndrome (ARDS), leading to pneumonia and respir

Совпадение в полном тексте источника
… Arthritis Rheum. 2014;43(4):458–469. doi: 10.1016/j.semarthrit.2013.08.001. 46. Kotch C., Barrett D., Teachey D.T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert. Rev. Clin. … Rheum. Dis. 2020 doi: 10.1136/annrheumdis-2020-217706. 72. Pontali E., Volpi S., Antonucci G., et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J. Allergy Clin. Immunol. 2020 doi: 10.1016/j.jaci.2020.05.002. 73. …

Position Statement on Multimodal Cardiac Imaging in Patients with Systemic Diseases - 2026.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Модуляторные эффекты традиционной китайской медицины и производные активных метаболитов на аутоиммунально-воспалительных путях сигнала при множестве склерозов: обзор повествования.

Множественный склероз (MS) — нервно-воспалительное заболевание с иммунной помощью, характеризующееся обезвоживанием, аксоновой травмой и обширным разрушением целостности центральной нервной системы. Экспериментальный аутоиммунный энцефаломиэлит (EAE) — наиболее часто применяемая модель для имитации патологических особенностей человека. В настоящее время еще многое предстоит сделать для совершенствования стратегии лечения MS. Все больше исследований показывают, что традиционная китайская медицина (TCM) и связанные с ней активные метаболиты полезны для лечения MS и умело регулируют уровни подстр

Совпадение в полном тексте источника
… Kuntze | N/A | Dry leaves | ( Lovera et al., 2015 ) Anthraquinones | Emodin | Rheum palmatum L. or Rheum tanguticum (Maxim. ex Regel) Balf. or Rheum officinale Baill. | Rhei radix Et rhizoma | Dry roots or rhizomes | ( Zheng et al., 2022 ) Naphthoquinones | Plumbagin | Plumbago zeylanica L. | N/A | Dry … Emodin is an anthraquinone derived from Rheum palmatum L. or Rheum tanguticum (Maxim. ex Regel) Balf. or R. officinale Baill., which possesses various bioactivities, including anti-inflammatory and anticancer properties. …

Autologous Hematopoietic Cell Transplant as an Effective Treatment Modality for Systemic Sclerosis and Multiple Myeloma.

Systemic sclerosis (SSc) is a multi-system disease characterized by a dysregulated immune system. Autologous hematopoietic cell transplantation (AHCT) is the only treatment that has been shown to confer significant benefit in controlling disease and improving survival for patients with SSc. A diagnosis of multiple myeloma (MM) after the diagnosis of SSc is rare and optimal treatment in such cases remains unclear. We here report a case of a female patient who was diagnosed with MM while she was undergoing evaluation for AHCT due to SSc. A novel conditioning regimen for AHCT, with therapeutic ef

Совпадение в полном тексте источника
… Ann Rheum Dis . 2017 ; 76 ( 8 ): 1327 – 1339 . doi: 10.1136/annrheumdis-2016-209909 27941129 12. Sullivan KM , Majhail NS , Bredeson C , et al. … Arthritis Rheum . 2003 ; 48 ( 8 ): 2246 – 2255 . doi: 10.1002/art.11073 12905479 27. Shouval R , Furie N , Raanani P , et al. Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis . …

IgG4-related kidney disease complicated with retroperitoneal fibrosis: A case report.

BACKGROUND: IgG4-related disease (IgG4-RD) is a chronic fibrotic disease mediated by immunity recognized by clinicians in recent years. When the kidney is involved, it is called IgG4-related kidney disease (IgG4-RKD). IgG4-related tubulointerstitial nephritis (IgG4-TIN) is a representative manifestation of IgG4-RKD. IgG4-TIN can cause obstructive nephropathy complicated by retroperitoneal fibrosis (RPF). Cases of IgG4-TIN complicated with RPF are rare. Glucocorticoids are the first-line therapeutic medication for IgG4-RD and can significantly improve renal function. CASE SUMMARY: Herein, we r

Совпадение в полном тексте источника
… Ann Rheum Dis. 2020;79:77–87. doi: 10.1136/annrheumdis-2019-216561. 15. Wu HHL, Wang CCY, Woywodt A, Ponnusamy A. Concurrent presentation of IgG4-related tubulointerstitial nephritis and ANCA MPO crescentic glomerulonephritis. Clin Nephrol Case Stud. 2022;10:47–53. doi: 10.5414/CNCS110852. 16. … Ann Rheum Dis. 2019;78:406–412. doi: 10.1136/annrheumdis-2018-214603. …

Cytotoxic CD4+ T cells: origin, biological functions, diseases and therapeutic targets.

Cytotoxic CD4+ T lymphocytes are a unique subset of CD4+ T cells characterized by their cytokine secretion and cytolytic activity. Unlike traditional CD4+ helper T cells, cytotoxic CD4+ T lymphocytes exhibit similar cytotoxicity to that of CD8+ T cells, revealing unexpected plasticity in CD4+ T-cell functions. This flexibility suggests that CD4+ T cells can transform and acquire effector functions beyond their conventional functions, emphasizing their importance in various immune responses. Despite the identification of cytotoxic CD4+ T lymphocytes decades ago, recent advancements have broaden

Lenalidomide-associated pure red cell aplasia during the treatment of POEMS syndrome: A case report and brief review of the literature.

Lenalidomide is widely used in the treatment of hematological malignancies, with bone marrow suppression being one of the most common hematological adverse effects associated with its use. However, lenalidomide-associated pure red cell aplasia (PRCA) remains exceptionally rare. The present study describes a case of PRCA secondary to lenalidomide therapy in a patient with POEMS syndrome. A 61-year-old woman diagnosed with POEMS syndrome received lenalidomide (25 mg/day) in combination with dexamethasone. Following 3 months of treatment, she developed severe anemia accompanied by a markedly redu

Совпадение в полном тексте источника
… Arthritis Rheum. 1997;40:786–787. doi: 10.1002/art.1780400430. 13. Kanai K, Sawai S, Sogawa K, Mori M, Misawa S, Shibuya K, Isose S, Fujimaki Y, Noto Y, Sekiguchi Y, et al. Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome. …

Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma.

Reactivation of Epstein-Barr virus (EBV) has been considered a very rare event among patients on immunomodulatory drugs (IMiDs) such as lenalidomide, and an association between the two has not well been recognized. We have recently experienced a rare case of multiple myeloma in which the patient had suffered EBV reactivation during long-term lenalidomide maintenance therapy. The patient subsequently developed EBV-associated lymphoproliferative disease (LPD) as well as EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH), which was fatal despite intensive treatment. Although rare, clinic

Совпадение в полном тексте источника
… Jog NR Young KA Munroe ME Harmon MT Guthridge JM Kelly JA Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals Ann Rheum Dis 2019 78 9 1235 1241 10.1136/annrheumdis-2019-215361 31217170 PMC6692217 …

Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis - retrospective study.

ObjectiveOsteoporosis is the most common bone tissue disease and it is characterized by a reduced bone mineral density (BMD). The main physiopathological mechanisms converge on the uncoupling between bone formation and resorption, thus leading to an enhanced risk of fractures. Several papers have documented the inverse relationships linking high inflammatory cytokines, anti-citrullinated protein antibodies, rheumatoid factor, and BMD in rheumatoid arthritis (RA). Rituximab (RTX) is a chimeric monoclonal antibody directed against the CD20 receptor of B cells. Since the Food and Drug Administrat…

Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation.

Galectin-3 is a beta-galactoside-binding lectin with an established association to inflammatory and fibrotic conditions. We investigated galectin-3 levels in 68 recipients of allogeneic hematopoietic cell transplantation (HCT) to look for associations with chronic graft-versus-host disease (cGVHD). Plasma galectin-3 concentrations were measured at 1 year post-HCT and correlated with clinical data collected from individual medical records. The median serum galectin-3 level at that time point was 14.9 ng/mL (range, 5.5-61.6), which was significantly higher than that among healthy controls (14.9

Совпадение в полном тексте источника
… Kobold AC vanGilst WH Hillege HL The fibrosis marker galectin-3 and outcome in the general population J Intern Med 2012 272 55 64 10.1111/j.1365-2796.2011.02476.x 22026577 [6] Ohshima S Kuchen S Seemayer CA Kyburz D Hirt A Klinzing S Galectin 3 and its binding protein in rheumatoid arthritis Arthritis Rheum …

Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape.

Autoimmune diseases remain a major cause of chronic morbidity despite substantial advances in targeted immunomodulatory therapies. In many autoantibody-mediated conditions, disease refractoriness and relapse are driven by long-lived plasma cells, which are largely resistant to conventional immunosuppression and upstream B cell-directed strategies. CD38, a surface molecule highly expressed on plasmablasts and plasma cells and functionally involved in immunometabolic regulation, has emerged as a promising therapeutic target to overcome this limitation. Clinical interest in anti-CD38 therapy has

Совпадение в полном тексте источника
… Int J Rheum Dis. 2025;28(8):e70395. 10.1111/1756-185x.70395. 27. Chiarenza DS, Mancini R, Bigatti C, Caridi G, Consolaro A, Natoli V, et al. Case report: single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis. … Ann Rheum Dis. 2023;82(11):1497–9. 31. Pleguezuelo DE, Díaz-Simón R, Cabrera-Marante O, Lalueza A, Paz-Artal E, Lumbreras C, et al. Case report: resetting the humoral immune response by targeting plasma cells with daratumumab in anti-phospholipid syndrome. Front Immunol. 2021;12:667515. 32. …

Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis.

BACKGROUND: The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing spondylitis is an inflammatory autoimmune disease and evidence showed that ankylosing spondylitis may be a microbiome-driven disease. RESULTS: To investigate the relationship between the gut microbiome and ankylosing spondylitis, a quantitative metagenomics study based on deep shotgun sequencing was performed, using gut microbial DNA from 211 Chinese individuals. A total of 23,709 genes and 12 metagenomic species were shown to be differentia

Совпадение в полном тексте источника
… Arthritis Rheum. 2007;56:2633–9. doi: 10.1002/art.22812. 8. Robinson PC, Leo PJ, Pointon JJ, Harris J, Cremin K, Bradbury LA, et al. … Arthritis Rheum. 1984;27:361–8. doi: 10.1002/art.1780270401. 39. Calin A. Can we define the outcome of ankylosing spondylitis and the effect of physiotherapy management? J Rheumatol. 1994;21:184–5. 40. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. …

Role of Exosomal Non-Coding RNAs in Bone-Related Diseases.

Bone-related diseases seriously affect the lives of patients and carry a heavy economic burden on society. Treatment methods cannot meet the diverse clinical needs of affected patients. Exosomes participate in the occurrence and development of many diseases through intercellular communication, including bone-related diseases. Studies have shown that exosomes can take-up and "package" non-coding RNAs and "deliver" them to recipient cells, thereby regulating the function of recipient cells. The exosomal non-coding RNAs secreted by osteoblasts, osteoclasts, chondrocytes, and other cells are invol

Совпадение в полном тексте источника
… Arthritis Rheum. 64 ( 6 ), 1697 – 1707 . 10.1002/art.34453 22392533 PMC3366018 Long F. Ornitz D. M. ( 2013 ). Development of the Endochondral Skeleton . Cold Spring Harbor Perspect. Biol. 5 ( 1 ), a008334 . 10.1101/cshperspect.a008334 PMC3579395 23284041 Lu J. Getz G. Miska E. A. … Rheum. Dis. 21 ( 9 ), 1659 – 1669 . 10.1111/1756-185X.13346 30345646 Zhang Y. Xie R.-l. Croce C. M. Stein J. L. Lian J. B. van Wijnen A. J. ( 2011 ). A Program of microRNAs Controls Osteogenic Lineage Progression by Targeting Transcription Factor Runx2 . Proc. Natl. Acad. …